Details

NameSymbolSector
PFIZER LTD.PFIZERPharmaceuticals
Open
5036
High
5036
Low
4864
Close
4874.8
Volume
11698
Exchange
nse
Time
14-Aug-2026

Outlook

Score:  

2.5

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Pfizer is  
Marubozu
Estimated Stoploss of Pfizer is ₹  
5036
Pfizer has a  
Bearishℹ
 pattern. 
Formation of  
Marubozu
 candle pattern indicates Pfizer has chances of  
Continuationℹ
 of the current trend. 

Trend

Pfizer is in  
Sideways trendℹ
. 
Price of Pfizer is  
Upℹ
 by  

4.39

%. 
Target
Buy @ 

4345.88

Sell @ 

4943.74

Current @ 

4874.8

Volume

The trade volumes of Pfizer have become  
Deficientℹ
Though the volume trend for Pfizer appears  
Bullishℹ
 the participants seem to be  
Weak Buyersℹ
The trade volume of Pfizer is  

Down

 by  

65.49

% 

Valuation

The current market price of Pfizer is  
Overvaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 4911cr and total assets worth ₹ 4911cr, the balance sheet of Pfizer is:  
Balancedℹ
. 
Cashflow
Pfizer has  
Excellentℹ
 cash flow because there is  

Surplus

 of  

₹ 383cr

. It is  
Upℹ
 by  

410.67

%. 

(*Mar 2025)

70.48% i.e. ₹ 659cr earned in operatingℹ
7.59% i.e. ₹ 71cr spent in investingℹ
21.93% i.e. ₹ 205cr spent in financingℹ
0% in otherℹ
Pfizer has  
Maintainedℹ
 cash flow because there is  

Surplus

 of  

₹ 75cr

. It is  
Upℹ
 by  

388.46

%. 

(*Mar 2024)

47.06% i.e. ₹ 256cr earned in operatingℹ
9.74% i.e. ₹ 53cr earned in investingℹ
43.2% i.e. ₹ 235cr spent in financingℹ
0% in otherℹ
Income
The income of Pfizer is  

₹ 684cr

 and  

Profit

 is :  

₹ 189cr

(*Sep 2025)

Pfizer Profit is down by:  

1.05

% and Income is Up by:  

2.09

% 

(*Sep 2025)

The income of Pfizer is  

₹ 670cr

 and  

Profit

 is :  

₹ 191cr

(*Jun 2025)

Pfizer Profit is down by:  

42.12

% and Income is Up by:  

5.35

% 

(*Jun 2025)

The income of Pfizer is  

₹ 636cr

 and  

Profit

 is :  

₹ 330cr

(*Mar 2025)

Pfizer Profit is up by:  

159.84

% and Income is Up by:  

9.66

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.